Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib
Digital Measures that Matter
Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III clinical trials in patients with schizophrenia.
Cobenfy marks a significant advancement in schizophrenia treatment, being the first new drug in decades. The drug targets the M1 and M4 muscarinic receptors, compared to antipsychotics which block dopamine receptors. This approach reduces both the positive and negative symptoms of schizophrenia more effectively2.
The Company notes that Bristol Myers Squibb used data from Cambridge Cognition’s CANTAB® cognitive assessments to conduct a post-hoc analysis of two Phase III trials. This analysis was recently published in The American Journal of Psychiatry1 titled ‘The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials’ . The CANTAB® assessments showed improvement in patients with pre-specified cognitive impairments after treatment with Cobenfy.
Cambridge Cognition believes this demonstrates CANTAB’s ability to measure improvements in cognitive performance effectively during the development of new schizophrenia drugs. We continue to support pharmaceutical companies to adopt CANTAB to leverage innovative study designs alongside digital data capture technology .
Rob Baker, Chief Operating Officer and Joint Managing Director, commented:
‘We believe this analysis proves that our digital assessment technologies can streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments in schizophrenia.’
Get in touch!
If you’d like to discuss any of the content further, or would like to get more insights from the Cambridge Cognition team, complete the form below and we will be in touch.
References
- Horan, William P., et al. “The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.” American Journal of Psychiatry (2024).
- Kaul, Inder, et al. “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.” The Lancet 403.10422 (2024): 160-170.
Author

Rob Baker
Chief of Product & Operations

Job title

Job title